PMID- 36048026
OWN - NLM
STAT- MEDLINE
DCOM- 20221220
LR  - 20230110
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 63
IP  - 13
DP  - 2022 Dec
TI  - Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or 
      refractory large B-cell lymphoma.
PG  - 3052-3062
LID - 10.1080/10428194.2022.2113526 [doi]
AB  - In the absence of a randomized head-to-head trial, an unanchored 
      matching-adjusted indirect comparison was performed to estimate the relative 
      treatment effects of axicabtagene ciloleucel (axi-cel; ZUMA-1) versus 
      lisocabtagene maraleucel (liso-cel; TRANSCEND-NHL-001) for treatment of 
      relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least two lines 
      of therapy. After matching, axi-cel and liso-cel had comparable objective 
      response rates and duration. Compared to liso-cel, axi-cel was associated with 
      improvements in overall survival (hazard ratio [HR]: 0.53 [95% CI: 0.34-0.82]) 
      and progression-free survival (HR: 0.61 [95% CI: 0.40-0.92]). Axi-cel was 
      associated with a higher rate of grade >/=3 cytokine release syndrome (odds ratio 
      [OR]: 3.64 [95% CI: 1.04-12.76]) and neurological events (OR: 3.45 [95% CI: 
      1.65-7.19]), with smaller differences estimated in scenario analyses including 
      ZUMA-1 safety management cohorts. Results suggest axi-cel improved survival 
      compared to liso-cel but with increased odds of specific adverse events.
FAU - Oluwole, Olalekan O
AU  - Oluwole OO
AUID- ORCID: 0000-0001-8525-9641
AD  - Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
FAU - Chen, Jenny M H
AU  - Chen JMH
AD  - PRECISIONheor, Vancouver, BC, Canada.
FAU - Chan, Keith
AU  - Chan K
AD  - PRECISIONheor, Vancouver, BC, Canada.
FAU - Patel, Anik R
AU  - Patel AR
AD  - Kite, A Gilead Company, Santa Monica, CA, USA.
FAU - Jansen, Jeroen P
AU  - Jansen JP
AD  - PRECISIONheor, Oakland, CA, USA.
FAU - Keeping, Sam
AU  - Keeping S
AUID- ORCID: 0000-0002-4281-1536
AD  - PRECISIONheor, Vancouver, BC, Canada.
FAU - Zheng, Yan
AU  - Zheng Y
AD  - Kite, A Gilead Company, Santa Monica, CA, USA.
FAU - Snider, Julia T
AU  - Snider JT
AUID- ORCID: 0000-0003-0017-4863
AD  - Kite, A Gilead Company, Santa Monica, CA, USA.
FAU - Locke, Frederick L
AU  - Locke FL
AUID- ORCID: 0000-0001-9063-6691
AD  - Moffitt Cancer Center, Tampa, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220901
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Biological Products)
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy
MH  - Progression-Free Survival
MH  - Odds Ratio
MH  - *Biological Products
MH  - Safety Management
MH  - Immunotherapy, Adoptive
MH  - Antigens, CD19
OTO - NOTNLM
OT  - CAR T-cell therapy
OT  - Large B-cell lymphoma
OT  - MAIC
OT  - axicabtagene ciloleucel
OT  - comparative efficacy
OT  - lisocabtagene maraleucel
EDAT- 2022/09/02 06:00
MHDA- 2022/12/21 06:00
CRDT- 2022/09/01 10:34
PHST- 2022/09/02 06:00 [pubmed]
PHST- 2022/12/21 06:00 [medline]
PHST- 2022/09/01 10:34 [entrez]
AID - 10.1080/10428194.2022.2113526 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2022 Dec;63(13):3052-3062. doi: 10.1080/10428194.2022.2113526. 
      Epub 2022 Sep 1.